Lemieux J, Provencher L, Perron L, Brisson J, Amireault C, Blanchette C, Maunsell E
Centre de recherche, Centre hospitalier universitaire (CHU) de Québec, Hôpital du Saint-Sacrement, 1050 chemin Sainte-Foy, Québec, QC, G1S 4L8, Canada,
Breast Cancer Res Treat. 2015 Jan;149(1):263-8. doi: 10.1007/s10549-014-3231-0. Epub 2014 Dec 16.
Scalp cooling can prevent chemotherapy-induced alopecia in some cancer patients. It is not used in all countries. No data are available regarding its impact, if any, on survival. The aim of this study was to compare overall survival according to whether or not scalp cooling was used during neoadjuvant or adjuvant chemotherapy for non-metastatic breast cancer. We conducted a retrospective cohort study of 1,370 women with non-metastatic invasive breast carcinoma who received chemotherapy in the neoadjuvant or adjuvant setting. A total of 553 women who used scalp cooling came from a tertiary breast cancer clinic in Quebec City (diagnosed between 1998 and 2002) and 817 were treated in other hospitals in the province of Quebec (between 1998 and 2003) where scalp cooling was not routinely available. Overall survival of women who used scalp cooling and those who did not was compared using Cox proportional hazards models. Median follow-up for the scalp-cooled and the non-scalp-cooled groups was 6.3 years and 8.0 years, respectively. Overall mortality was no different (adjusted hazard ratio 0.89, 95 % confidence interval: 0.68-1.17, p = 0.40) among scalp-cooled women, compared to those not getting scalp cooling. Among women getting neoadjuvant or adjuvant chemotherapy for non-metastatic breast cancer, scalp cooling used to prevent chemotherapy-induced alopecia had no negative effect on survival. To our knowledge, this is the first study to compare survival of women who used scalp cooling to that of women who did not.
头皮冷却可预防部分癌症患者化疗所致脱发。并非所有国家都使用该方法。目前尚无关于其对生存率影响（若有影响）的数据。本研究旨在比较在非转移性乳腺癌新辅助或辅助化疗期间使用或未使用头皮冷却的患者的总生存率。我们对1370例接受新辅助或辅助化疗的非转移性浸润性乳腺癌女性进行了一项回顾性队列研究。共有553例使用头皮冷却的女性来自魁北克市的一家三级乳腺癌诊所（1998年至2002年期间确诊），817例在魁北克省其他医院接受治疗（1998年至2003年期间），这些医院未常规提供头皮冷却。使用Cox比例风险模型比较了使用头皮冷却和未使用头皮冷却的女性的总生存率。头皮冷却组和未头皮冷却组的中位随访时间分别为6.3年和8.0年。与未进行头皮冷却的女性相比，头皮冷却女性的总死亡率无差异（调整后风险比0.89，95%置信区间：0.68 - 1.17，p = 0.40）。在接受非转移性乳腺癌新辅助或辅助化疗的女性中，用于预防化疗所致脱发的头皮冷却对生存率无负面影响。据我们所知，这是第一项比较使用头皮冷却与未使用头皮冷却的女性生存率的研究。
